Journal articleNeuro Oncol2022
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.
- Journal
- Neuro Oncol
- Published
- 1 June 2022
- Citations
- 140
- License
- cc by-nc
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try